Personalized Treatment of Urogenital Cancers Depends on the Microbiome

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03962920

Enrollment

Registered

2019-05-24

Start date

2020-05-01

Completion date

2027-05-01

Last updated

2024-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Microbial Disease

Brief summary

This is a randomized controlled trial where patients undergoing surgical treatment for urogenital cancers will be randomized in a two arms study: surgical treatment + antibiotics OR surgical treatment + placebo.

Interventions

DRUGTigecycline 50 MG

Local instillation of drug directly to the tumour tissue

OTHERPlacebo

Local instillation of sterile water directly to the tumour tissue

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

40 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Biopsy verified diagnosis of urological cancer, localized disease

Exclusion criteria

* Hospitalization within three months of surgery * Antibiotics within three months of surgery * Infectious disease, including UTI's within three months of surgery * History of cancers of the genitourinary tract * Diabetes

Design outcomes

Primary

Measure	Time frame	Description
recurrence rate after surgical treatment of tumour	5 years after treatment	recurrence rate after surgical treatment of tumour

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026